» Articles » PMID: 37543985

Association of Radioactive Iodine Treatment in Differentiated Thyroid Cancer and Cardiovascular Death: a Large Population-based Study

Overview
Publisher Springer
Specialty Endocrinology
Date 2023 Aug 6
PMID 37543985
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The risk of cardiovascular diseases' death (CVD) in patients with differentiated thyroid cancer (DTC) treated with radioactive iodine (RAI) after surgery has not been adequately studied.

Methods: Data of DTC patients who received RAI after surgery were retrieved from the Surveillance, Epidemiology, and End Result (SEER) database (2004-2015). Standardized mortality rate (SMR) analysis was used to evaluate the CVD risk in patients with RAI vs general population. A 1:1 propensity score matching (PSM) was applied to balance inter-group bias, and Pearson's correlation coefficient was used to detect collinearity between variables. The Cox proportional hazard model and multivariate competing risk model were utilized to evaluate the impact of RAI on CVD. At last, we curved forest plots to compare differences in factors significantly associated with CVD or cancer-related deaths.

Results: DTC patients with RAI treatment showed lower SMR for CVD than general population (RAI: SMR = 0.66, 95% CI 0.62-0.71, P < 0.05). After PSM, Cox proportional hazard regression demonstrated a decreased risk of CVD among patients with RAI compared to patients without (HR = 0.76, 95% CI 0.6-0.97, P = 0.029). However, in competing risk regression analysis, there was no significant difference (adjusted HR = 0.82, 95% CI 0.66-1.01, P = 0.11). The independent risk factors associated with CVD were different from those associated with cancer-related deaths.

Conclusion: The CVD risk between DTC patients treated with RAI and those who did not was no statistical difference. Noteworthy, they had decreased CVD risk compared with the general population.

Citing Articles

The Impact of Thyroid Hormone Imbalance on Cardiovascular Health: A Population-Based Study.

Anwar U, Arshad J, Naeem U, Zahid A, Jehan A, Ramzan S Cureus. 2025; 16(12):e76457.

PMID: 39867074 PMC: 11769698. DOI: 10.7759/cureus.76457.


The Interplay Between High Cumulative Doses of Radioactive Iodine and Type 2 Diabetes Mellitus: A Complex Cardiovascular Challenge.

Stanciu A, Bolovan M, Zamfir-Chiru-Anton A, Voiosu C, Dabla P, Stanciu M Int J Mol Sci. 2025; 26(1.

PMID: 39795891 PMC: 11720250. DOI: 10.3390/ijms26010037.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Kitahara C, Sosa J . The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016; 12(11):646-653. PMC: 10311569. DOI: 10.1038/nrendo.2016.110. View

3.
Miller K, Nogueira L, Mariotto A, Rowland J, Yabroff K, Alfano C . Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69(5):363-385. DOI: 10.3322/caac.21565. View

4.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

5.
Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View